Mitefosine, a PI 3-kinase and Akt inhibitor belonging to the alkylphosphocholines, has also been shown to inhibit anti-IgE induced histamine release from skin mast cells. Experimental studies show that this agent can reduce cytokines IL-1β, IL-4, and IL-6 in certain skin tissue cells and also strongly impede the esterification of cholesterol. Additionally, Miltefosine displays the ability to methylate CDP-choline (sc-200713) and phosphatidylethanolamine which interferes with biosynthesis of phosphatidylcholine. Furthermore, data suggests that this compound can slow down the formation of sphingomyelin, which promotes intracellular accumulation of ceramide. Miltefosine is an inhibitor of CCT and PKC.
1. Chugh, P., et al. 2008. Retrovirology. 5: 11. PMID: 18237430 2. Bäumer, W., et al. 2010. Eur. J. Pharmacol. 628: 226-232. PMID: 19917276 3. Jiménez-López, J.M., et al. 2010. Lipids Health Dis. 9: 33. PMID: 20338039
Soluble in water (10 mg/ml), DMSO (800 µg/ml), ethanol (1 mg/ml), PBS(pH7.2) (2.5 mg/ml), and DMF (~50 µg/ml).
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
CheshenkoCheshenko, N. et al. (PubMed 23507869) used Miltefosine, a PI3K/Akt inhibitor, to determine if Akt signaling contributes to herpes simplex virus (HSV) cell entry. Inhibition of Akt signaling by Miltefosine caused inhibited HSV-induced calcium release, viral entry, and plaque formation. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn